15730 A randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CBP-201 administered to healthy adult subjects

Background: Suzhou Connect Biopharmaceuticals is developing CBP-201 for the treatment of atopic dermatitis (AD). CBP-201 is a fully human monoclonal antibody targeting IL-4Rα that blocks IL-4/IL-13 signaling.